Phase I/II clinical trial (NCT02541370) has reported feasibility, controllable toxicities, and effective activity of CD133-directed CAR-T in patients with CD133+ hepatocellular carcinoma, pancreatic carcinomas, and colorectal carcinomas 116, 117. This evidence concerns the gene PROM1 and exocrine pancreatic carcinoma.